Howard McLeod, one of the six researchers ousted at Moffitt Cancer Center under allegations of undisclosed conflicts of interest stemming from their work in China, is publicly disputing his former employer’s characterization of his involvement with academic institutions there.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
